2026-04-14T05:54:06Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4771362024-11-04T08:22:14Zcom_2072_98col_2072_378192

MiR-146a targets Fos expression in human cardiac cells Palomer, Xavier Capdevila-Busquets, E. Botteri, G. Davidson, Mercy M. Rodríguez, Cristina Martínez-González, José Vidal, Francisco Barroso, Emma Chan, Tung O. Feldman, Arthur M. Vázquez-Carrera, Manuel Universitat Autònoma de Barcelona Cardiac remodeling Fos Inflammation Matrix metalloproteinase-9 Mir-146a miR-146a is a microRNA whose transcript levels are induced in the heart upon activation of NF-κB, a transcription factor induced by proinflammatory molecules (such as TNF-α) that is strongly related to the pathogenesis of cardiac disorders. The main goal of this study consisted of studying new roles of miR-146a in cardiac pathological processes caused by the pro-inflammatory cytokine TNF-α.Our results demonstrate that miR-146a transcript levels were sharply increased in cardiac ventricular tissue of transgenic mice with specific overexpression of TNF-α in the heart, and also in a cardiomyocyte cell line of human origin (AC16) exposed to TNF-α. Among all the in silico predicted miR-146a target genes, Fos mRNA and protein levels notably decreased after TNF-α treatment or miR-146a overexpression. These changes correlated with a diminution in the DNA-binding activity of AP-1, the Fos-containing transcription factor complex. Interestingly, AP-1 inhibitionwas accompanied by a reduction in matrix metalloproteinase (MMP)-9 mRNA levels in human cardiac cells. The specific regulation of this MMP by miR-146a was further confirmed at the secretion and enzymatic activity levels, aswell as after anti-miR-mediated miR-146a inhibition. The results reported here demonstrate that Fos is a direct target of miR-146a activity and that downregulation of the Fos-AP-1 pathway bymiR-146a has the capacity to inhibit MMP-9 activity. Given that MMP-9 is an AP-1 target gene involvedin cardiac remodeling,myocardial dysfunction and progression of heart failure, these findings suggest that miR-146a might be a new and promising therapeutic tool for treating cardiac disorders associated with enhanced inflammation in the heart. 2024-11-04T08:22:14Z 2024-11-04T08:22:14Z 2024-11-04T08:22:14Z 2015 Article http://hdl.handle.net/2072/477136 Ministerio de Ciencia e Innovación SAF2009-06939 Ministerio de Economía y Competitividad SAF2012-30708 Ministerio de Economía y Competitividad SAF2012-40127 Disease Models & Mechanisms ; Vol. 8 Núm. 9 (january 2015), p. 1081-1091 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/